“ Everyone deserves mental health support – but not everyone needs the same kind,” said Dr Jenna Glover, Chief Clinical Officer at Headspace.“ We were an early-pioneer of end-to-end mental health care, knowing that people experience better outcomes when they engage in the right combination of human and self-guided care, not just a onesize-fits-all approach. We’ re now taking that to the next level with our stratified care model, which is designed to adapt with members as they move through their care journeys, ensuring they get what they need, when they need it.”

Traditional and new employee assistance programmes( EAPs) often default to therapy, regardless of clinical necessity or individual preference. With this in mind, Headspace is taking a stratified approach to care, leveraging conversational AI to evaluate a member’ s needs, symptoms and risk factors at the onset and then intelligently guide them to the most appropriate level of care within Headspace’ s ecosystem – whether coaching, therapy, psychiatry, self-guided tools or work-life services. By ensuring timely, appropriate support based on each person’ s needs, a stratified approach prevents downstream costs associated with worsening symptoms, comorbid conditions, and lost productivity – helping employers and health plans lower overall mental health spend.

groundbreaking applications using Roche’ s recently unveilled next-generation sequencing( NGS) Sequencing By Expansion( SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab’ s research community.

The first project will see Broad Clinical Labs using the SBX technology to advance research into trio-based whole genome sequencing of critically ill newborns and their biological parents. This programme aims to establish a future state where whole genome sequencing becomes a routine component of clinical care in neonatal intensive care units( NICUs) – enabling precise, timely diagnoses and improved outcomes for infants with suspected genetic disorders.

“ The SBX technology was designed with both clinical impact and scientific discovery in mind, and offers the next-generation of fast, scalable sequencing solutions,” said Matt Sause, CEO of Roche Diagnostics.“ Collaborating with Broad Clinical Labs, a leader in clinical genomics and omics research, accelerates our ability to deliver on that promise and support better outcomes for patients through cuttingedge genomic technology.”

10 www. intelligenthealth. tech